We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

New Method Predicts Efficacy of Common Breast Cancer Drug

Breast cancer cells.
Breast cancer cells. Credit: Dr. Cecil Fox/ National Cancer Institute

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "New Method Predicts Efficacy of Common Breast Cancer Drug"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

This is the first time a biomarker can accurately predict the efficacy of a conventional chemotherapy treatment.


The study published in Nature Communications was performed on samples of HER2-negative breast cancer, which accounts for 85% of diagnosed breast tumors.


“Patients with high levels of proteins CDK4 and filamin have a positive response rate in 90% of cases," says Miguel A. Quintela-Fandino, head of the CNIO Breast Cancer Clinical Unit.


Precision oncology aims at pointing out which drug is likely to work in every specific cancer patient. At the moment these targeted therapies are only available for 5% of cancers. The study carried out by CNIO researchers Miguel A. Quintela-Fandino and Silvana Mouron, together with oncology units from several Spanish hospitals, has discovered a way to identify whether one of the most commonly used drugs in conventional chemotherapy for various types of cancer, paclitaxel, will be effective in each patient. The work has been published in Nature Communications.


Targeted therapies have been based mostly on the analysis of genetic mutations in each cancer. Quintela and Mouron's research focuses on HER2-negative breast cancer, which accounts for 85% of breast cancer diagnoses and is due, in most cases, not to a few but to several oncogenic mutations –designing targeted therapies based on genetic mutations for this tumor is therefore a difficult goal to achieve.


Quintela and Mouron, however, did not perform a genomic analysis (of genes), but a proteomic analysis (of proteins). They had shown in previous research that, even when a large number of oncogenic mutations are present, only a small number of protein alterations appear.


Two proteins, CDK4 and filamin, predict response to paclitaxel


In other words, while in most cancers no common genetic markers are found in patients who do not respond to a given drug, common protein-related markers can indeed be found. Proteins are the molecules that carry out most of the functions of cells; the genes (in the DNA molecule) contain the information to produce all the proteins needed by the organism.


The CNIO group analyzed HER2-negative breast cancer samples from 130 patients treated with paclitaxel, one of the most widely used drugs against breast, ovarian, lung, bladder, prostate, melanoma, esophageal and other cancers. They looked for similarities in the expression of proteins in the samples from patients who did respond to paclitaxel, and found two proteins specifically related to paclitaxel response: CDK4 and filamin.

"First predictors of response to conventional chemotherapy"

The researchers showed that this association appears when paclitaxel is used, but not when other drugs are used.


"We found that patients with high levels of CDK4 and filamin have a positive response rate in 90% of cases," summarizes Miguel A. Quintela-Fandino, principal investigator and head of the CNIO Breast Cancer Clinical Unit.


"The study identifies the first specific predictive factors for a conventional chemotherapy treatment, for which only indirect or imperfect predictive markers were known until now. Instead, CDK4 and filmanin A are associated with paclitaxel activity in a very precise manner," adds this CNIO researcher.


The work is not immediately applicable to the clinic. "For this discovery to be incorporated into the oncological therapeutic arsenal, epidemiological and clinical studies would have to be carried out," says Quintela-Fandino.


Reference: Mouron S, Bueno MJ, Lluch A, et al. Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A. Nat Commun. 2022;13(1):7529. doi: 10.1038/s41467-022-35065-z


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement